Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 31 October 2025 - 5 November 2025

‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

Key facts (updated Nov 5, 2025): The story: Biology is moving from thought experiment to flight plan Europe’s HOBI‑WAN pilot (Hydrogen‑Oxidizing Bacteria in Weightlessness As a source of Nutrition) is ESA’s clearest sign yet that microbial food production will be part of living off‑Earth. The agency says the demonstrator feeds a bacterial culture with stored gases (H₂, O₂, CO₂) to…
5 November 2025
··
COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

Below is a full breakdown of COMPASS Pathways’ recent performance, news, expert commentary, industry positioning, and an analysis of the stock’s fundamentals, technicals, and future scenarios. Stock Performance Overview (Nov 2025) COMPASS Pathways’ stock has experienced considerable volatility in 2025, mirroring the company’s clinical trial news cycle. As of November 4, 2025, CMPS trades in the mid-$5 range (around $5.95–$6.00),…
4 November 2025
···
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Company Overview & 2025 Developments Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals (pets) and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This breadth has helped Zoetis capture the #1 industry position – in 2023 its $8.5B in sales exceeded the next-largest competitor…
4 November 2025
···
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta (SRPT) Stock Collapses 80% on FDA Bombshell – Is a Big Rebound Coming?

SRPT Stock Price & Recent Performance Sarepta’s stock has experienced a dramatic collapse in 2025, wiping out years of gains. After starting the year near all-time highs, SRPT shares have plunged by over 80% year-to-date Marketbeat. As of early November 2025, the stock trades in the mid-teens, down from about $120–$130 at the start of the year. In fact, the…
4 November 2025
····
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Company Background and Business Model Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference (RNAi) therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technology Phiopharma. Originally known as RXi Pharmaceuticals (founded ~2011), Phio rebranded and refocused on immuno-oncology. Its…
3 November 2025
····
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

Stock Performance: Skyrockets and Crashes UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch in late September when Phase 1/2 trial data showed a remarkable 75% reduction in disease progression with AMT-130 – news…
3 November 2025
···
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Company Overview and Background Acrivon Therapeutics is a Boston-area biotech (NASDAQ: ACRV) founded in 2018, emerging with a mission to revolutionize cancer treatment through precision medicine Stockanalysis. The company’s name “Acrivon” is derived from “accurate” or “precision,” reflecting its core approach: develop targeted oncology drugs hand-in-hand with diagnostics that pinpoint the patients who will respond. Acrivon’s proprietary platform, AP3 (Acrivon…
3 November 2025
···
Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou’s Game-Changing CAR-T Results Caribou Biosciences – a clinical-stage biotech focusing on genome-edited cell therapies – stunned the biotech world with new data on November 3, 2025, showcasing that its off-the-shelf CAR-T cell treatments can achieve remission rates on par with personalized CAR-T therapies Statnews. In an early-morning webcast, Caribou revealed Phase 1 trial outcomes from two programs: vispa-cel for…
3 November 2025
··
Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Stock Price & Recent Performance Illumina’s stock has whipsawed in late 2025. After drifting near its 52-week lows (~$69 in late 2024), it ticked up to the mid-$90s by mid-October 2025. Following the Oct. 30 earnings report, ILMN exploded higher: by Oct. 31 it was trading around $120 ts2.tech Marketbeat. (MarketBeat confirms ILMN closed $123.64 on 10/31, +24.9% for the…
1 November 2025
····
Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Q3 2025 Earnings: Beat Expectations and Lifted Guidance Illumina’s latest quarterly report (Q3 FY2025) provided a much-needed spark for investors. The San Diego-based genomics giant reported $1.084 billion in revenue for Q3, slightly above Wall Street estimates (~$1.07B) and flat versus the same quarter last year Investing. While flat growth might not sound impressive, it exceeded Illumina’s own guidance range, marking…
31 October 2025
···
1 … 16 17 18 19 20 … 24

Stock Market Today

  • Cantor Fitzgerald Raises Price Target for Regeneron Pharmaceuticals (NASDAQ:REGN)
    February 2, 2026, 11:58 AM EST. Cantor Fitzgerald increased its price target on Regeneron Pharmaceuticals (NASDAQ:REGN) from $740 to $800, maintaining an "overweight" rating, signaling a potential 5% upside. Other brokerages also raised forecasts, with BMO Capital Markets at $850, Guggenheim at $865, and Evercore ISI at $875. Regeneron's shares rose 2.7% to $761.32 amid increased trading volume. The biotech giant posted strong Q4 results with EPS of $11.44 beating estimates, and revenues up 2.5% year-over-year to $3.88 billion. The company holds a solid balance sheet with low debt and robust margins. Market consensus rates the stock as a "Moderate Buy" with an average price target near $790, reflecting optimism about Regeneron's growth prospects.
Go toTop